BR112013007696A2 - compound, pharmaceutical composition, uses of said compound and said composition - Google Patents

compound, pharmaceutical composition, uses of said compound and said composition

Info

Publication number
BR112013007696A2
BR112013007696A2 BR112013007696A BR112013007696A BR112013007696A2 BR 112013007696 A2 BR112013007696 A2 BR 112013007696A2 BR 112013007696 A BR112013007696 A BR 112013007696A BR 112013007696 A BR112013007696 A BR 112013007696A BR 112013007696 A2 BR112013007696 A2 BR 112013007696A2
Authority
BR
Brazil
Prior art keywords
compound
composition
pharmaceutical composition
virus
pharmaceutical
Prior art date
Application number
BR112013007696A
Other languages
Portuguese (pt)
Inventor
B Shankar Bandarpalle
Hu Bin
Zhong Bin
J Lavey Brian
Shen Changmao
A Coburn Craig
Yang De-Yi
Sun Frei
Nair Anilkumar G
Zhou Guowei
Wu Hao
A Kozlowski Joseph
M Keertikar Kartik
Chen Lei
Tong Ling
P Dwyer Michael
Wong Michael
B Selyutin Oleg
Zeng Qingbei
Rizvi Razia
B Rosenblum Stuart
Ji Tao
Yu Wensheng
Jiang Yueheng
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/077493 external-priority patent/WO2012040923A1/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112013007696A2 publication Critical patent/BR112013007696A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

composto, composição farmacêutica, usos do referido composto e da referida composição. são fornecidos derivados de indol tetracíclicos de fórmula (1), são farmaceuticamente aceitáveis do mesmo e suas composições farmacêuticas, nos quais a, a<39>,g, r^1 ^, r^ 15^, u, v, v. w, w, x, x<39>, y, y<39> são como definidos na invenção. também é fornecido o uso destes derivados para tratar infecção por vírus da hepatite c (hepatitis c virus, hcv).compound, pharmaceutical composition, uses of said compound and said composition. are provided tetracyclic indole derivatives of formula (1), are pharmaceutically acceptable thereof and their pharmaceutical compositions, wherein a, a, a, a, a, a, v. w, w, x, x <39>, y, y <39> are as defined in the invention. Use of these derivatives to treat hepatitis c virus (hepatitis c virus, hcv) infection is also provided.

BR112013007696A 2010-09-29 2011-09-28 compound, pharmaceutical composition, uses of said compound and said composition BR112013007696A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/077493 WO2012040923A1 (en) 2010-09-29 2010-09-29 Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
US201061426724P 2010-12-23 2010-12-23
PCT/CN2011/001638 WO2012041014A1 (en) 2010-09-29 2011-09-28 Tetracyclic indole derivatives for treating hepatitis c virus infection

Publications (1)

Publication Number Publication Date
BR112013007696A2 true BR112013007696A2 (en) 2019-09-24

Family

ID=45891857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013007696A BR112013007696A2 (en) 2010-09-29 2011-09-28 compound, pharmaceutical composition, uses of said compound and said composition

Country Status (8)

Country Link
EP (1) EP2621931A4 (en)
JP (1) JP2013538831A (en)
KR (1) KR20140001879A (en)
AU (1) AU2011307953B2 (en)
BR (1) BR112013007696A2 (en)
CA (1) CA2811662A1 (en)
MX (1) MX2013003631A (en)
WO (1) WO2012041014A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
NZ619205A (en) 2009-05-13 2015-04-24 Gilead Pharmasset Llc Antiviral compounds
JP5530514B2 (en) 2009-06-11 2014-06-25 アッヴィ・バハマズ・リミテッド Antiviral compounds for treating HCV infection
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8354419B2 (en) 2009-07-16 2013-01-15 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2809261A1 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
TWI482766B (en) 2011-07-09 2015-05-01 Sunshine Lake Pharma Co Ltd As a spiro compound for hepatitis C virus inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
MD4589C1 (en) 2011-09-16 2019-03-31 Gilead Pharmasset Llc Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
CN103848818B (en) 2012-11-29 2017-03-15 广东东阳光药业有限公司 Simultaneously cycle compound, pharmaceutical composition and their applications in medicine as hepatitis c inhibitor
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
WO2014110687A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2014110688A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases
NZ625087A (en) 2013-01-31 2017-05-26 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN111116563B (en) * 2013-06-06 2023-07-04 上海爱博医药科技有限公司 Compound for inhibiting hepatitis C virus, pharmaceutical composition and application thereof
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN105530933B (en) 2013-07-17 2018-12-11 百时美施贵宝公司 For treating the combination product comprising biphenyl derivatives of HCV
ES2900570T3 (en) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9725464B2 (en) * 2013-10-30 2017-08-08 Merck Sharp & Dohme Corp. Process for preparing tetracyclic heterocycle compounds
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US20170166586A1 (en) 2014-07-11 2017-06-15 Hongming Li Process for making tetracyclic heterocycle compounds
WO2016196932A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Process for preparing substituted tetracyclic heterocycle compounds
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN108290904B (en) * 2015-12-10 2020-10-09 正大天晴药业集团股份有限公司 Deuterium modified elbasvir derivatives, pharmaceutical compositions containing the same and uses thereof
WO2017181947A1 (en) * 2016-04-20 2017-10-26 深圳市塔吉瑞生物医药有限公司 Substituted diamine carbamate, and pharmaceutical composition and application thereof
WO2018032467A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
WO2018032468A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
RU2659388C1 (en) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Nucleotides including n-[(s)-1-cyclobutoxycarbonyl]phosphoramidate fragment, their analogs and their application
RU2650610C1 (en) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Antiviral composition and method of its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7745636B2 (en) * 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8865756B2 (en) * 2008-12-03 2014-10-21 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
BRPI0922366B8 (en) * 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc compound, pharmaceutical composition and use of a compound
UA108351C2 (en) * 2009-03-27 2015-04-27 Hepatitis C Virus Replication Inhibitors

Also Published As

Publication number Publication date
EP2621931A4 (en) 2014-03-19
KR20140001879A (en) 2014-01-07
AU2011307953B2 (en) 2014-07-31
EP2621931A1 (en) 2013-08-07
JP2013538831A (en) 2013-10-17
AU2011307953A1 (en) 2013-04-04
WO2012041014A1 (en) 2012-04-05
MX2013003631A (en) 2013-10-01
CA2811662A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
BR112013007696A2 (en) compound, pharmaceutical composition, uses of said compound and said composition
CO6592102A2 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
UY32759A (en) HEPATITIS C VIRUS INHIBITORS
NI200700102A (en) TETRACICLIC INDOL DERIVATIVES AS ANTIVIRICAL AGENTS
MX2010008531A (en) Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors.
MX2010008699A (en) Heterocyclic derivatives as hepatitis c virus inhibitors.
CL2012001176A1 (en) Benzimidazole-imidazole derivative compounds, hepatitis c virus (hcv) inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; use in the prevention or treatment of hcv infection.
HK1166788A1 (en)
UY31183A1 (en) PIRAZINONA DERIVATIVES AND PROCESSES FOR THEIR PREPARATION
EA200901241A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
CL2012000573A1 (en) Compounds derived from biphenyl-pyrrolidinyl-imidazole; pharmaceutical composition comprising them; its use in the treatment of an hcv viral infection.
WO2011041713A3 (en) Piperazinyl antiviral agents
SV2005001920A (en) &#34;NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS&#34;
HRP20070342A2 (en) Indole derivatives for treating viral infections
CO6761348A2 (en) Antiviral compounds
EA201390822A1 (en) MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
EA201491179A1 (en) 2 &#39;, 4&#39;-DIFFOROR-2&#39;-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS AN INHIBITORS REPLICATION RNA HEPATITIS C VIRUS
CO6290682A2 (en) INHIBITING FUSIONED TRICICLIC COMPOUNDS OF HEPATITIS VIRUS C.
EA201290576A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
CL2008002539A1 (en) Substituted indole derivative compounds; pharmaceutical composition comprising them; and its use for the treatment of a viral infection
EA201290575A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
CO6390076A2 (en) NS5A HCV INHIBITORS
BR112012018345A2 (en) &#34;heteroaryl compounds, as well as compositions and uses thereof&#34;
MX2012002925A (en) INHIBITORS OF&lt;i&gt; FLAVIVIRIDAE&lt;/i&gt; VIRUSES.
MX2009012613A (en) Heteroaryl substituted thiazoles and their use as antiviral agents.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.